TMEM43-S358L mutation enhances NF-κBTGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy

Abstract

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiac muscle disease that accounts for approximately 30% sudden cardiac death in young adults. The Ser358Leu mutation of transmembrane protein 43 (TMEM43) was commonly identified in the patients of highly lethal and fully penetrant ARVD subtype, ARVD5. Here, we generated TMEM43 S358L mouse to explore the underlying mechanism. This mouse strain showed the classic pathologies of ARVD patients, including structural abnormalities and cardiac fibrofatty. TMEM43 S358L mutation led to hyper-activated nuclear factor κB (NF-κB) activation in heart tissues and primary cardiomyocyte cells. Importantly, this hyper activation of NF-κB directly drove the expression of pro-fibrotic gene, transforming growth factor beta (TGFβ1), and enhanced downstream signal, indicating that TMEM43 S358L mutation up-regulates NF-κB-TGFβ signal cascade during ARVD cardiac fibrosis. Our study partially reveals the regulatory mechanism of ARVD development.

Key words： TMEM43; ARVD; NF-κB; TGFβ; fibrosis; knock-in mouse

References

1 Asimaki A, Tandri H, Duffy ER, Winterfield JR, Mackey-Bojack S, Picken MM, Cooper LT, Wilber DJ, Marcus FI, Basso C (2011) Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 4:743–752

2 Baskin B, Skinner JR, Sanatani S, Terespolsky D, Krahn AD, Ray PN, Scherer SW, Hamilton RM (2013) TMEM43 mutations associated with arrhythmogenic right ventricular cardiomyopathy in non-Newfoundland populations. Hum Genet 132:1245–1252

3 Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R (2010) PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 23:343–352

4 Bengtsson L, Otto H (2008) LUMA interacts with emerin and influences its distribution at the inner nuclear membrane. J Cell Sci 121:536–548

5 Campian ME, Verberne HJ, Hardziyenka M, de Groot EA, van Moerkerken AF, van Eck-Smit BL, Tan HL (2010) Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Nucl Med Mol Imaging 37:2079–2085

6 Campuzano O, Alcalde M, Iglesias A, Barahona-Dussault C, Sarquella-Brugada G, Benito B, Arzamendi D, Flores J, Leung TK, Talajic M (2012) Arrhythmogenic right ventricular cardiomyopathy: severe structural alterations are associated with inflammation. J Clin Pathol 65:1077–1083

7 Capulzini L, Brugada P, Brugada J, Brugada R (2010) Arrhythmia and right heart disease: from genetic basis to clinical practice. Rev Esp Cardiol 63:963–983

8 Chavez E, Castro-Sanchez L, Shibayama M, Tsutsumi V, Moreno MG, Muriel P (2012) Sulfasalazine prevents the increase in TGFbeta, COX-2, nuclear NFkappaB translocation and fibrosis in CCl4-induced liver cirrhosis in the rat. Hum Exp Toxicol 31:913–920

9 Christensen AH, Andersen CB, Tybjaerg-Hansen A, Haunso S, Svendsen JH (2011) Mutation analysis and evaluation of the cardiac localization of TMEM43 in arrhythmogenic right ventricular cardiomyopathy. Clin Genet 80:256–264

10 Cranefield PF (1975) The conduction of the cardiac impulse : the slow response and cardiac arrhythmias. Futura Pub. Co., Mount Kisco, p 404

11 Grabiner BC, Blonska M, Lin PC, You Y, Wang D, Sun J, Darnay BG, Dong C, Lin X (2007) CARMA3 deficiency abrogates G proteincoupled receptor-induced NF-{kappa}B activation. Genes Dev 21:984–996

12 Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195–2224

13 Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344–362

14 Haywood AF, Merner ND, Hodgkinson KA, Houston J, Syrris P, Booth V, Connors S, Pantazis A, Quarta G, Elliott P (2013) Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. Eur Heart J 34:1002–1011

15 Hodgkinson KA, Connors SP, Merner N, Haywood A, Young TL, McKenna WJ, Gallagher B, Curtis F, Bassett AS, Parfrey PS (2013) The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p. S358L mutation in TMEM43. Clin Genet 83:321–331

16 Jiang C, Lin X (2012) Regulation of NF-kappaB by the CARD proteins. Immunol Rev 246:141–153

17 Jiang C, Zhu Y, Zhou Z, Gumin J, Bengtsson L, Wu W, Songyang Z, Lang FF, Lin X (2016) TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-kappaB activation and tumor progression. Oncogene 36:2813

18 Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663

19 Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J (2007) Bcl10 and Malt1 control lysophosphatidic acid-induced NFkappaB activation and cytokine production. Proc Natl Acad Sci USA 104:134–138

20 Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93:5860–5865

21 Li J, Swope D, Raess N, Cheng L, Muller EJ, Radice GL (2011) Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of {beta}-catenin signaling. Mol Cell Biol 31:1134–1144

22 Lombardi R, da Graca Cabreira-Hansen M, Bell A, Fromm RR, Willerson JT, Marian AJ (2011) Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 109:1342–1353

23 Maass DL, White J, Horton JW (2005) Nitric oxide donors alter cardiomyocyte cytokine secretion and cardiac function. Crit Care Med 33:2794–2803

24 McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nunez G (2007) CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 104:139–144

25 Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol 12:325–338

26 Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, Kupprion C, Ramadanova K, Thierfelder L, McKenna W (2008) Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82:809–821

27 Milting H, Klauke B, Christensen AH, Musebeck J, Walhorn V, Grannemann S, Munnich T, Saric T, Rasmussen TB, Jensen HK (2015) The TMEM43 Newfoundland mutation p. S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. Eur Heart J. 36:872–881

28 Muthappan P, Calkins H (2008) Arrhythmogenic right ventricular dysplasia. Prog Cardiovasc Dis 51:31–43

29 Niederbichler AD, Westfall MV, Su GL, Donnerberg J, Usman A, Vogt PM, Ipaktchi KR, Arbabi S, Wang SC, Hemmila MR (2006) Cardiomyocyte function after burn injury and lipopolysaccharide exposure: single-cell contraction analysis and cytokine secretion profile. Shock 25:176–183

30 Pan D, Lin X (2013) Epithelial growth factor receptor-activated nuclear factor kappaB signaling and its role in epithelial growth factor receptor-associated tumors. Cancer J 19:461–467

31 Park KS (2016) Catalpol reduces the production of inflammatory mediators via PPAR-gamma activation in human intestinal Caco-2 cells. J Nat Med 70:620–626

32 Pilichou K, Bezzina CR, Thiene G, Basso C (2011) Arrhythmogenic cardiomyopathy: transgenic animal models provide novel insights into disease pathobiology. Circ Cardiovasc Genet 4:318–326

33 Schirmer EC, Florens L, Guan T, Yates JR III, Gera L (2003) Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science 301:1380–1382

34 Shambharkar PB, Blonska M, Pappu BP, Li H, You Y, Sakurai H, Darnay BG, Hara H, Penninger J, Lin X (2007) Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J 26:1794–1805

35 Uitto J, Kouba D (2000) Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 24(Suppl 1):S60–S69

36 Verrecchia F, Mauviel A (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13:3056–3062

37 Wada K, Kamisaki Y (2010) Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications. Nihon Rinsho 68:278–283

38 Wang D, You Y, Lin PC, Xue L, Morris SW, Zeng H, Wen R, Lin X (2007) Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA 104:145–150

39 Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC (2013) Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10:15–26

40 Xu F, Liu C, Zhou D, Zhang L (2016) TGF-beta/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem 64:157–167

41 Zhang M, Guo Y, Fu H, Hu S, Pan J, Wang Y, Cheng J, Song J, Yu Q, Zhang S (2015) Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from Hmgb1/TLR4/NFkappaB/IL-1beta signaling. Cell Death Dis 6: e1847

42 Zhou J, Liang Y, Pan JX, Wang FF, Lin XM, Ma RJ, Qu F, Fang JQ (2015) Protein extracts of Crassostrea gigas alleviate CCl(4)-induced hepatic fibrosis in rats by reducing the expression of CTGF, TGF-beta1 and NF-kappaB in liver tissues. Mol Med Rep 11:2913–2920